Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7590 in Healthy Participants and Moderate-to-Severe IBD
NCT07758101Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of SHR-7590 in inflammatory bowel disease (IBD) (5 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Adverse Events at Day 281 and Serious Adverse Events at Day 281. Started Aug 2026; status: recruiting.
02
Drugs
SHR-7590
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07758101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758101.